HR Execs on the Move

MicroMD

www.micromd.com

 
MicroMD is a Youngstown, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Mike Crider
Sales Manager Profile

Similar Companies

Safe Ride Services

Safe Ride Services is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hormone Treatment Center

Hormone Treatment Center is a Bellaire, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Health Alliance Plan

We are a non-profit, Michigan-based company and a subsidiary of the Henry Ford Health System, one of the nation`s leading health care systems. We provide health plans for everyone -- individuals and companies of all sizes. Since 1960, we`ve partnered with leading doctors, hospitals, employers and community organizations to enhance the lives of those we touch. We offer six distinct health insurance lines: • Group Insured Commercial • Individual • Medicare • Medicaid • Self-Funded • Network Leasing HAP also provides: • Award-winning wellness programs • Community outreach • Digital health tools • Disease management services • Personalized customer service

Trinity Communications

Trinity Communications is a Media, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.